PCSA has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
PCSA has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Processa Pharmaceuticals's Total Stockholders Equity for the quarter that ended in Dec. 2024 was $1.70 Mil. Processa Pharmaceuticals's Total Assets for the quarter that ended in Dec. 2024 was $3.23 Mil.
The historical rank and industry rank for Processa Pharmaceuticals's Equity-to-Asset or its related term are showing as below:
During the past 13 years, the highest Equity to Asset Ratio of Processa Pharmaceuticals was 0.96. The lowest was -783.67. And the median was 0.76.
The historical data trend for Processa Pharmaceuticals's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Processa Pharmaceuticals Annual Data | |||||||||||||||||||||
Trend | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | Dec24 | |||||||||||
Equity-to-Asset | Get a 7-Day Free Trial |
![]() |
![]() |
0.91 | 0.96 | 0.87 | 0.86 | 0.53 |
Processa Pharmaceuticals Quarterly Data | ||||||||||||||||||||
Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | Dec24 | |
Equity-to-Asset | Get a 7-Day Free Trial |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
0.86 | 0.89 | 0.79 | 0.75 | 0.53 |
For the Biotechnology subindustry, Processa Pharmaceuticals's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Processa Pharmaceuticals's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Processa Pharmaceuticals's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Processa Pharmaceuticals's Equity to Asset Ratio for the fiscal year that ended in Dec. 2024 is calculated as
Equity to Asset (A: Dec. 2024 ) | = | Total Stockholders Equity | / | Total Assets |
= | 1.696 | / | 3.229 | |
= |
Processa Pharmaceuticals's Equity to Asset Ratio for the quarter that ended in Dec. 2024 is calculated as
Equity to Asset (Q: Dec. 2024 ) | = | Total Stockholders Equity | / | Total Assets |
= | 1.696 | / | 3.229 | |
= |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Processa Pharmaceuticals (NAS:PCSA) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Thank you for viewing the detailed overview of Processa Pharmaceuticals's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.
George K Ng | officer: Chief Executive Officer | C/O SORRENTO THERAPEUTICS, INC., 6042 CORNERSTONE COURT WEST, SUITE B, SAN DIEGO CA 92121 |
Justin W Yorke | director | C/O JMG EXPLORATION, 180 SOUTH LAKE AVENUE, PASADENA CA 91101 |
David Young | director, 10 percent owner, officer: President & CEO | 8850 STANFORD BOULEVARD, SUITE 2500, COLUMBIA MD 21045 |
Patrick Lin | officer: Chief Business - Strategy Off | 7380 COCA COLA DRIVE, SUITE 106, HANOVER MD 21076 |
Wendy Guy | officer: Chief Administrative Officer | 7380 COCA COLA DRIVE, SUITE 106, HANOVER MD 21076 |
James H Stanker | officer: Chief Financial Officer | 9008 SHADYBROOK DRIVE, FREDERICK MD 21701 |
Khoso Baluch | director | 1430 US HIGHWAY 206, SUITE 200, BEDMINSTER NJ 07921 |
James R Neal | director | 2910 SEVENTH STREET, BERKELEY CA 94710 |
Virgil Thompson | director | 319 SOUTH NARDO, SOIANA BEACH CA 92075 |
Geraldine Pannu | director | 7380 COCA COLA DRIVE, SUITE 106, HANOVER MD 21076 |
Robert Michael Floyd | officer: Chief Operating Officer | C/O PROCESSA PHARMACEUTICALS, INC., 7300 COCA COLA DRIVE, SUITE 106, HANOVER MD 21076 |
James E Besser | 10 percent owner | 3 WEST HILL PLACE, BOSTON MA 02114 |
Khalid Islam | director | C/O IMMUNOMEDICS, INC., 300 THE AMERICAN ROAD, MORRIS PLAINS NJ 07950 |
Sian Bigora | officer: Chief Development Officer | 7380 COCA COLA DRIVE, SUITE 106, HANOVER MD 21076 |
From GuruFocus
By Marketwired • 01-28-2025
By Marketwired • 04-11-2024
By Marketwired • 10-30-2024
By GuruFocus Research • 02-08-2024
By Marketwired • 06-11-2024
By GuruFocus Research • 02-08-2024
By Marketwired • 01-30-2025
By GuruFocus Research • 02-08-2024
By GuruFocus Research • 02-08-2024
By Marketwired • 07-17-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.